Galina Selivanova

About me
Publications
Grants
CV
Public outreach and news

About me

Galina Selivanova is a Professor of Cell and Tumor Biology and one of the pioneers in research on p53 – a protein with a central role in the protection against cancer.

Articles

Article: BRITISH JOURNAL OF CANCER. 2022;127(11):2060-2071
Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
Zhou X; Santos GS; Zhan Y; Oliveira MMS; Rezaei S; Singh M; Peuget S; Westerberg LS; Johnsen JI; Selivanova G
Article: MOLECULAR CANCER THERAPEUTICS. 2022;21(10):1524-1534
Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
Zhan Y; Zhou X; Peuget S; Singh M; Peyser BD; Fan Z; Selivanova G
Article: ONCOGENE. 2022;41(15):2173-2186
Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization
Aschtgen M-S; Fragkoulis K; Sanz G; Normark S; Selivanova G; Henriques-Normark B; Peuget S
Article: FRONTIERS IN MOLECULAR BIOSCIENCES. 2022;9:823195
Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
Grinkevich VV; Vema A; Fawkner K; Issaeva N; Andreotti V; Dickinson ER; Hedstrom E; Spinnler C; Inga A; Larsson L-G; Karlen A; Wilhelm M; Barran PE; Okorokov AL; Selivanova G; Zawacka-Pankau JE
Article: CANCER DISCOVERY. 2021;11(12):3090-3105
Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
Zhou X; Singh M; Santos GS; Guerlavais V; Carvajal LA; Aivado M; Zhan Y; Oliveira MMS; Westerberg LS; Annis DA; Johnsen JI; Selivanova G
Journal article: CLINICAL CANCER RESEARCH. 2021;27(17):4943
Editor's Note: Dual Targeting of Wild-Type and Mutant p53 by Small-molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro.
Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
Article: ISCIENCE. 2020;23(12):101785
Class IV Lasso Peptides Synergistically Induce Proliferation of Cancer Cells and Sensitize Them to Doxorubicin
Guerrero-Garzon JF; Madland E; Zehl M; Singh M; Rezaei S; Aachmann FL; Courtade G; Urban E; Rueckert C; Busche T; Kalinowski J; Cao Y-R; Jiang Y; Jiang C-L; Selivanova G; Zotchev SB
Article: BREAST CANCER RESEARCH. 2020;22(1):80
Identification and targeting of selective vulnerability rendered by tamoxifen resistance
Singh M; Zhou X; Chen X; Santos GS; Peuget S; Cheng Q; Rihani A; Arner ESJ; Hartman J; Selivanova G
Article: CANCER RESEARCH. 2020;80(7):1538-1550
Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds
Peuget S; Zhu J; Sanz G; Singh M; Gaetani M; Chen X; Shi Y; Saei AA; Visnes T; Lindstrom MS; Rihani A; Moyano-Galceran L; Carlson JW; Hjerpe E; Joneborg U; Lehti K; Hartman J; Helleday T; Zubarev R; Selivanova G
Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(2):E598-598
p53 CRISPR Deletion Affects DNA Structure and Nuclear Architecture
Rangel-Pozzo A; Booth S; Yu PLI; Singh M; Selivanova G; Mai S
Article: SCIENTIFIC REPORTS. 2020;10(1):1049
Pifithrin-α alters p53 post-translational modifications pattern and differentially inhibits p53 target genes
Zhu J; Singh M; Selivanova G; Peuget S
Article: HAEMATOLOGICA. 2020;105(1):170-181
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia
Demir S; Boldrin E; Sun Q; Hampp S; Tausch E; Eckert C; Ebinger M; Handgretinger R; te Kronnie G; Wiesmueller L; Stilgenbauer S; Selivanova G; Debatin K-M; Meyer LH
Article: CELL DEATH AND DISEASE. 2019;10(11):845
RITA requires eIF2α-dependent modulation of mRNA translation for its anti-cancer activity
Ristau J; van Hoef V; Peuget S; Zhu J; Guan B-J; Liang S; Hatzoglou M; Topisirovic I; Selivanova G; Larsson O
Article: SCIENTIFIC REPORTS. 2019;9(1):2379
Prediction of response to anti-cancer drugs becomes robust via network integration of molecular data
Franco M; Jeggari A; Peuget S; Bottger F; Selivanova G; Alexeyenko A
Article: CANCER LETTERS. 2019;442:341-350
RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism
Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
Article: CELL CYCLE. 2018;17(24):2697-2715
MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts
Zhang F; Zakaria SM; Tabor VH; Singh M; Tronnersjo S; Goodwin J; Selivanova G; Bartek J; Castell A; Larsson L-G
Journal article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2017;292(48):19607
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs (vol 280, pg 30384, 2005)
Bykov VJN; Issaeva N; Zache N; Shilov A; Hultcrantz M; Bergman J; Selivanova G; Wiman KG
Journal article: KLINISCHE PADIATRIE. 2016;228(03)
Targeting mutant TP53 in ALL
Demir S; Selivanova G; Tausch E; Wiesmüller L; Stilgenbauer S; te Kronnie G; Debatin K; Meyer L
Article: CELL DEATH AND DISEASE. 2015;6(1):e1616
The conserved Trp114 residue of thioredoxin reductase 1 has a redox sensor-like function triggering oligomerization and crosslinking upon oxidative stress related to cell death
Xu J; Eriksson SE; Cebula M; Sandalova T; Hedstrom E; Pader I; Cheng Q; Myers CR; Antholine WE; Nagy P; Hellman U; Selivanova G; Lindqvist Y; Arner ESJ
Article: FRONTIERS IN MOLECULAR BIOSCIENCES. 2015;2:39
The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors
Dickinson ER; Jurneczko E; Nicholson J; Hupp TR; Zawacka-Pankau J; Selivanova G; Barran PE
Article: CARCINOGENESIS. 2014;35(10):2273-2282
Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53
Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmueller L
Article: CELL DEATH AND DIFFERENTIATION. 2014;21(9):1493-1502
Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis
Li H; Zhang Y; Stroese A; Tedesco D; Gurova K; Selivanova G
Article: CELL DEATH AND DIFFERENTIATION. 2014;21(4):612-623
sROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis
Shi Y; Nikulenkov F; Zawacka-Pankau J; Li H; Gabdoulline R; Xu J; Eriksson S; Hedstroem E; Issaeva N; Kel A; Arner ESJ; Selivanova G
Article: CELL DEATH AND DISEASE. 2013;4(10):e881
APR-246/PRIMA-1^MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
Peng X; Zhang M-Q; Conserva F; Hosny G; Selivanova G; Bykov VJN; Arner ESJ; Wiman KG
Article: CLINICAL CANCER RESEARCH. 2013;19(18):5092-5103
Dual Targeting of Wild-Type and Mutant p53 by Small Molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro
Burmakin M; Shi Y; Hedstrom E; Kogner P; Selivanova G
Article: CELL DEATH AND DIFFERENTIATION. 2012;19(12):1992-2002
Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis
Nikulenkov F; Spinnler C; Li H; Tonelli C; Shi Y; Turunen M; Kivioja T; Ignatiev I; Kel A; Taipale J; Selivanova G
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2012;287(35):29336-29347
Protein Kinase Cα (PKCα) Regulates p53 Localization and Melanoma Cell Survival Downstream of Integrin αv in Three-dimensional Collagen and in Vivo
Smith SD; Enge M; Bao W; Thullberg M; Costa TDF; Olofsson H; Gashi B; Selivanova G; Stromblad S
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2011;286(48):41600-41615
Inhibition of Glycolytic Enzymes Mediated by Pharmacologically Activated p53 TARGETING WARBURG EFFECT TO FIGHT CANCER
Zawacka-Pankau J; Grinkevich VV; Huenten S; Nikulenkov F; Gluch A; Li H; Enge M; Kel A; Selivanova G
Article: CELL DEATH AND DIFFERENTIATION. 2011;18(11):1736-1745
Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX
Spinnler C; Hedstrom E; Li H; de Lange J; Nikulenkov F; Teunisse AFAS; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
Article: CELL CYCLE. 2011;10(19):3346-3358
Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2
Li H; Lakshmikanth T; Garofalo C; Enge M; Spinnler C; Anichini A; Szekely L; Karre K; Carbone E; Selivanova G
Article: CLINICAL CANCER RESEARCH. 2011;17(9):2830-2841
PRIMA-1^Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53
Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
Article: CELL CYCLE. 2011;10(2):301-307
PRIMA-1^Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo
Bao W; Chen M; Zhao X; Kumar R; Spinnler C; Thullberg M; Issaeva N; Selivanova G; Stromblad S
Article: CELL CYCLE. 2010;9(9):1847-1855
Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA
Zhao CY; Grinkevich VV; Nikulenkov F; Bao W; Selivanova G
Article: CANCER RESEARCH. 2010;70(8):3372-3381
Rescue of p53 Function by Small-Molecule RITA in Cervical Carcinoma by Blocking E6-Mediated Degradation
Zhao CY; Szekely L; Bao W; Selivanova G
Article: CELL CYCLE. 2009;8(21):3584-3591
p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA
Hedstrom E; Eriksson S; Zawacka-Pankau J; Arner ESJ; Selivanova G
Article: CANCER RESEARCH. 2009;69(15):6241-6248
HIPK2 Regulation by MDM2 Determines Tumor Cell Response to the p53-Reactivating Drugs Nutlin-3 and RITA
Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
Journal article: CANCER CELL. 2009;16(1):79
MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53
Enge M; Bao W; Hedström E; Jackson SP; Moumen A; Selivanova G
Article: CANCER CELL. 2009;15(5):441-453
Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis
Grinkevich VV; Nikulenkov F; Shi Y; Enge M; Bao W; Maljukova A; Gluch A; Kel A; Sangfelt O; Selivanova G
Article: CANCER CELL. 2009;15(3):171-183
MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53
Enge M; Bao W; Hedstrom E; Jackson SP; Moumen A; Selivanova G
Article: EXPERIMENTAL CELL RESEARCH. 2009;315(3):451-461
Tumor-specific induction of apoptosis by a p53-reactivating compound
Hedstrom E; Issaeva N; Enge M; Selivanova G
Journal article: APMIS. 2008;116(5):434-435
40 Identification of tumor-suppressor-gene candidates in small cell lung cancer, which combined with a p53 reactivating molecule, can be used for cancer gene therapy
Zandi R; Selivanova G; Poulsen HS
Journal article: APMIS. 2008;116(5):434-435
40Identification of tumor-suppressor-gene candidates in small cell lung cancer, which combined with a p53 reactivating molecule, can be used for cancer gene therapy
Zandi R; Selivanova G; Poulsen HS
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;141(4):445-453
Mutated and non-mutated TP53 as targets in the treatment of leukaemia
Nahi H; Selivanova G; Lehmann S; Mollgard L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Article: EUROPEAN JOURNAL OF CANCER. 2007;43(12):1877-1882
Kaposi's sarcoma herpesvirus load in biopsies of cutaneous and oral Kaposi's sarcoma lesions
Pak F; Mwakigonja AR; Kokhaei P; Hosseinzadeh N; Pyakurel P; Kaaya E; Bogdanovic G; Selivanova G; Biberfeld P
Article: CELL DEATH AND DIFFERENTIATION. 2007;14(3):411-421
Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis
Liu T; Laurell C; Selivanova G; Lundeberg J; Nilsson P; Wiman KG
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2007;282(4):2466-2472
Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and -independent manner
Zawacka-Pankau J; Issaeva N; Hossain S; Pramanik A; Selivanova G; Podhajska AJ
Article: EMBO JOURNAL. 2006;25(21):5191-5200
The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity
Okorokov AL; Sherman MB; Plisson C; Grinkevich V; Sigmundsson K; Selivanova G; Milner J; Orlova EV
Article: APOPTOSIS : AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH. 2006;11(2):221-233
HAMLET triggers apoptosis but tumor cell death is independent of caspases, Bcl-2 and p53
Hallgren O; Gustafsson L; Irjala H; Selivanova G; Orrenius S; Svanborg C
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;132(2):230-236
PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion
Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
Journal article: BLOOD. 2005;106(11):5536
RITA Activates p53 Function in Chronic Lymphocytic Leukaemia Cells and Induces Apoptosis.
Nahi H; Merup M; Möllgård L; Selivanova G; Paul C
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2005;280(34):30384-30391
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs
Bykov VJN; Issaeva N; Zache N; Shilov A; Hultcrantz M; Bergman J; Selivanova G; Wiman KG
Article: ONCOGENE. 2005;24(21):3484-3491
PRIMA-1^MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov VJN; Zache N; Stridh H; Westman J; Bergman J; Selivanova G; Wiman KG
Article: INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 2005;81(2):125-138
Dose-response for radiation-induced apoptosis, residual 53BP1 foci and DNA-loop relaxation in human lymphocytes
Torudd J; Protopopova M; Sarimov R; Nygren J; Eriksson S; Marková E; Chovanec M; Selivanova G; Belyaev IY
Article: JOURNAL OF CUTANEOUS PATHOLOGY. 2005;32(1):21-27
HHV-8/KSHV during the development of Kaposi's sarcoma: evaluation by polymerase chain reaction and immunohistochemistry
Pak F; Pyakural P; Kokhaei P; Kaaya E; Pourfathollah AA; Selivanova G; Biberfeld P
Article: NATURE MEDICINE. 2004;10(12):1321-1328
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors
Issaeva N; Bozko P; Enge M; Protopopova M; Verhoef LGGC; Masucci M; Pramanik A; Selivanova G
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;127(3):285-291
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion
Nahi H; Lehmann S; Mollgard L; Bengtzen S; Selivanova G; Wiman KG; Paul C; Merup M
Journal article: EJC SUPPLEMENTS. 2004;2(8):62
200 Mutant p53 reactivation by PRIMA-1: a novel strategy for cancer therapy
Wiman K; Bykov V; Issaeva N; Zache N; Bergman J; Selivanova G
Article: DISCOVERY MEDICINE. 2004;4(20):28-30
Rescue of the p53 tumor suppressor by a rationally designed molecule.
Selivanova G; Fersht A
Article: CELL CYCLE. 2003;2(6):592-595
Inhibition of p53 Activity In Vitro and in Living Cells by a Synthetic Peptide Derived from Its Core Domain
Protopopova M; Selivanova G
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2003;100(23):13303-13307
Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide
Issaeva N; Friedler A; Bozko P; Wiman KG; Fersht AR; Selivanova G
Article: EUROPEAN JOURNAL OF CANCER. 2003;39(13):1828-1834
Small molecules that reactivate mutant p53
Bykov VJN; Selivanova G; Wiman KG
Article: CARCINOGENESIS. 2002;23(12):2011-2018
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database
Bykov VJN; Issaeva N; Selivanova G; Wiman KG
Article: ONCOGENE. 2002;21(14):2119-2129
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells
Rippin TM; Bykov VJN; Freund SMV; Selivanova G; Wiman KG; Fersht AR
Article: NATURE MEDICINE. 2002;8(3):282-288
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov VJN; Issaeva N; Shilov A; Hultcrantz M; Pugacheva E; Chumakov P; Bergman J; Wiman KG; Selivanova G
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2002;99(3):1532-1537
Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2-and HPV-E6-induced proteolysis
Heessen S; Leonchiks A; Issaeva N; Sharipo A; Selivanova G; Masucci MG; Dantuma NP
Article: METHODS IN MOLECULAR BIOLOGY. 2002;203:279-288
p53 induction as an indicator of DNA damage.
Selivanova G
Article: ONCOGENE. 2001;20(39):5503-5510
Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway
Falck J; Lukas C; Protopopova M; Lukas J; Selivanova G; Bartek J
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2001;276(25):22699-22708
Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein - Functional consequences of their interaction
Grigorian M; Andresen S; Tulchinsky E; Kriajevska M; Carlberg C; Kruse C; Cohn M; Ambartsumian N; Christensen A; Selivanova G; Lukanidin E
Journal article: EUROPEAN JOURNAL OF CANCER. 2001;37:s139
p53-induced apoptosis and new cancer therapy
Wiman KG; Bykov VJ; Issaeva N; Shilov A; Bergman J; Selivanova G
Article: APOPTOSIS : AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH. 2001;6(1-2):133-137
Inactivation of Myc-induced p53-dependent apoptosis in human tumors
Henriksson M; Selivanova G; Lindström M; Wiman KG
Article: ONCOGENE. 2000;19(45):5123-5133
Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells
Xu DW; Wang Q; Gruber A; Björkholm M; Chen ZG; Zaid A; Selivanova G; Peterson C; Wiman KG; Pisa P
Article: NUCLEIC ACIDS RESEARCH (NAR). 2000;28(20):4005-4012
p53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core
Zotchev SB; Protopopova M; Selivanova G
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1999;265(1):1-6
p53-induced apoptosis as a safeguard against cancer
Asker C; Wiman KG; Selivanova G
Article: MOLECULAR AND CELLULAR BIOLOGY. 1999;19(5):3395-3402
Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain
Selivanova G; Ryabchenko L; Jansson E; Iotsova V; Wiman KG
Article: SEMINARS IN CANCER BIOLOGY. 1998;8(5):369-378
Reactivation of mutant p53: a new strategy for cancer therapy
Selivanova G; Kawasaki T; Ryabchenko L; Wiman KG
Article: NATURE MEDICINE. 1997;3(6):632-638
Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain
Selivanova G; Iotsova V; Okan I; Fritsche M; Strom M; Groner B; Grafstrom RC; Wiman KG
Article: NUCLEIC ACIDS RESEARCH (NAR). 1996;24(18):3560-3567
The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region
Selivanova G; Iotsova V; Kiseleva E; Strom M; Bakalkin G; Grafstrom RC; Wiman KG
Article: NUCLEIC ACIDS RESEARCH (NAR). 1995;23(3):362-369
P53 BINDS SINGLE-STRANDED-DNA ENDS THROUGH THE C-TERMINAL DOMAIN AND INTERNAL DNA SEGMENTS VIA THE MIDDLE DOMAIN
BAKALKIN G; SELIVANOVA G; YAKOVLEVA T; KISELEVA E; KASHUBA E; MAGNUSSON KP; SZEKELY L; KLEIN G; TERENIUS L; WIMAN KG
Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1994;91(1):413-417
P53 BINDS SINGLE-STRANDED-DNA ENDS AND CATALYZES DNA RENATURATION AND STRAND TRANSFER
BAKALKIN G; YAKOVLEVA T; SELIVANOVA G; MAGNUSSON KP; SZEKELY L; KISELEVA E; KLEIN G; TERENIUS L; WIMAN KG
Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1993;90(12):5455-5459
EBNA-5, AN EPSTEIN-BARR VIRUS-ENCODED NUCLEAR ANTIGEN, BINDS TO THE RETINOBLASTOMA AND P53 PROTEINS
SZEKELY L; SELIVANOVA G; MAGNUSSON KP; KLEIN G; WIMAN KG
Journal article: RUSSIAN JOURNAL OF GENETICS. 1992;28(5):66-72
ISOLATION AND ANALYSIS OF PROTEASE DEFICIENT MUTANTS OF BACILLUS-AMYLOLIQUEFACIENS
PLOTNIKOVA TG; SELIVANOVA GN; JOMANTAS JV; KOZLOV YI
Show more

All other publications

Review: NATURE REVIEWS CANCER. 2024;24(3):192-215
Translating p53-based therapies for cancer into the clinic
Peuget S; Zhou X; Selivanova G
Editorial comment: CANCER DISCOVERY. 2023;13(5):1043-1045
MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation
Peuget S; Selivanova G
Conference publication: CANCER SCIENCE. 2023;114:249
Pharmacological activation of p53 triggers viral mimicry response thereby promoting anti-tumor immunity
Selivanova G; Zhou X; Singh M; Sanz G; Guerlavais V; Carvajal LA; Aivado M; Annis A; Zhan Y; Oliveira M; Westerberg L; Johnsen JI
Preprint: BIORXIV. 2021
Novel allosteric mechanism of dual p53/MDM2 and p53/MDM4 inhibition by a small molecule
Grinkevich VV; Aparna V; Fawkner K; Issaeva N; Andreotti V; Dickinson ER; Hedström E; Spinnler C; Inga A; Larsson L-G; Karlén A; Wilhelm M; Barran PE; Okorokov AL; Selivanova G; Zawacka-Pankau JE
Editorial comment: CANCERS. 2021;13(19):4850
p53-Dependent Repression: DREAM or Reality?
Peuget S; Selivanova G
Review: JOURNAL OF MOLECULAR CELL BIOLOGY. 2019;11(7):586-599
Inhibition of p53 inhibitors: progress, challenges and perspectives
Sanz G; Singh M; Peuget S; Selivanova G
Preprint: BIORXIV. 2018
Novel allosteric mechanism of p53 activation by small molecules for targeted anticancer therapy
Zawacka-Pankau J; Grinkevich V; Burmakin M; Vema A; Fawkner K; Issaeva N; Andreotti V; Dickinson E; Hedström E; Spinnler C; Inga A; Larsson L-G; Karlén A; Tarasova O; Poroikov V; Lavrenov S; Preobrazhenskaya M; Barran P; Okorokov A; Selivanova G
Preprint: BIORXIV. 2018
Robust and clinically relevant prediction of response to anti-cancer drugs via network integration of molecular profiles
Franco M; Jeggari A; Peuget S; Böttger F; Selivanova G; Alexeyenko A
Preprint: SSRN ELECTRONIC JOURNAL. 2018
Novel Allosteric Mechanism of P53 Activation by Small Molecules for Targeted Anticancer Therapy
Zawacka-Pankau J; Grinkevich VV; Burmakin M; Vema A; Ridderstråle K; Issaeva N; Andreotti V; Dickinson ER; Hedström E; Spinnler C; Inga A; Larsson L-G; Karlén A; Tarasova O; Poroikov V; Lavrenov S; Preobrazhenskaya M; Wilhelm M; Barran PE; Okorokov AL; Selivanova G
Corrigendum: CANCER CELL. 2017;31(5):724-726
Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis (vol 15, pg 441, 2009)
Grinkevich VV; Nikulenkov F; Shi Y; Enge M; Bao W; Maljukova A; Gluch A; Kel A; Sangfelt O; Selivanova G
Corrigendum: CELL DEATH AND DISEASE. 2017;8(4):e2751
APR-246/PRIMA-1^MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase (vol 4, e881, 2013)
Peng X; Zhang M-Q; Conserva F; Hosny G; Selivanova G; Bykov VJN; Arner ESJ; Wiman KG
Conference publication: ANNALS OF HEMATOLOGY. 2017;96:S73
Targeting Mutant p53 in Acute Lymphoblastic Leukemia as a Novel Therapeutic Strategy
Demir S; Sun Q; Tausch E; Stilgenbauer S; Kronnie GT; Wiesmueller L; Selivanova G; Debatin K-M; Meyer LH
Conference publication: PEDIATRIC BLOOD AND CANCER. 2017;64:S70
Therapeutic Targeting of Mutant P53 in Pediatric Acute Lymphobastic Leukemia
Demir S; Sun Q; Tausch E; Stilgenbauer S; te Kronnie G; Eckert C; Wiesmueller L; Selivanova G; Debatin KM; Meyer L
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2016;39:200
Mutant p53 as a novel therapeutic target in Acute Lymphoblastic Leukemia
Demir S; Selivanova G; Tausch E; Wiesmueller L; Stilgenbauer S; te Kronnie G; Debatin K-M; Meyer LH
Conference publication: HAEMATOLOGICA. 2016;101:28
FUNCTIONAL RESTORATION OF MUTANT P53 AND CELL DEATH SENSITIZATION IN ACUTE LYMPHOBLASTIC LEUKEMIA
Demir S; Selivanova G; Tausch E; Wiesmueller L; Stilgenbauer S; te Kronnie G; Debatin KM; Meyer LH
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2016;39:117
APR-246 targets pediatric acute lymphoblastic leukemia carrying mutant P53
Demir S; Selivanova G; Tausch E; Wiesmueller L; Stilgenbauer S; te Kronnie G; Debatin K-M; Meyer L
Conference publication: BLOOD. 2015;126(23):903
Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia
Demir S; Selivanova G; Tausch E; Wiesmueller L; Stilgenbauer S; Te Kronnie G; Debatin K-M; Meyer LH
Conference publication: CANCER RESEARCH. 2015;75:503
The PPM1D encoded phosphatase Wip1 is a novel oncogene and potential therapeutic target in neuroblastoma and medulloblastoma
Miloseyic J; Treis D; Wickstrom M; Fransson S; Eissler N; Syeinbjornsson B; Baryawno N; Tanino K; Selivanova G; Sakaguchi K; Martinsson T; Johnsen JI; Kogner P
Review: JOURNAL OF INTERNAL MEDICINE. 2015;277(2):248-259
Pharmacological reactivation of p53 as a strategy to treat cancer
Zawacka-Pankau J; Selivanova G
Conference publication: PEDIATRIC BLOOD AND CANCER. 2015;62:S332
THE PPM1D ENCODED PHOSPHATASE WIP1 IS A NOVEL ONCOGENE AND POTENTIAL THERAPEUTIC TARGET IN NEUROBLASTOMA AND MEDULLOBLASTOMA
Milosevic J; Treis D; Malin M; Fransson S; Sveinbjornsson B; Eissler N; Baryawno N; Tanino K; Selivanova G; Sakaguchi K; Martinsson T; Johnsen JI; Kogner P
Review: FEBS LETTERS. 2014;588(16):2628-2638
Wild type p53 reactivation: From lab bench to clinic
Selivanova G
Book chapter: P53 IN THE CLINICS. 2013;p. 231-255
p53-Reactivating Molecules as Research Tools and Anticancer Drugs
Grinkevich VV; Warnecke A; Selivanova G
Editorial comment: ONCOIMMUNOLOGY. 2012;1(4):541-543
A novel facet of tumor suppression by p53 Induction of tumor immunogenicity
Li H; Lakshmikanth T; Carbone E; Selivanova G
Review: SEMINARS IN CANCER BIOLOGY. 2010;20(1):46-56
Therapeutic targeting of p53 by small molecules
Selivanova G
Editorial comment: CELL. 2009;139(7):1220-1222
Integrins and Mutant p53 on the Road to Metastasis
Selivanova G; Ivaska J
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2009;4(9):S592-S593
Identification of tumour-suppressor-gene candidates in small cell lung cancer, which combined with a p53 reactivating molecule, can be used for cancer gene therapy
Zandi R; Selivanova G; Willumsen BM; Poulsen HS
Conference publication: CANCER RESEARCH. 2009;69
Identification of tumor-suppressor-gene candidates in small cell lung cancer, which combined with a p53 reactivating molecule can be used for cancer gene therapy.
Zandi R; Selivanova G; Willumsen B; Poulsen H
Review: TOXICOLOGY AND APPLIED PHARMACOLOGY. 2008;232(3):487-497
The p53-mediated cytotoxicity of photodynamic therapy of cancer: Recent advances
Zawacka-Pankau J; Krachulec J; Grulkowski I; Bielawski KP; Selivanova G
Conference publication: APMIS. 2008;116(5):434-435
Identification of tumor-suppressor-gene candidates in small cell lung cancer, which combined with a p53 reactivating molecule, can be used for cancer gene therapy
Zandi R; Selivanova G; Poulsen HS
Review: ONCOGENE. 2007;26(15):2243-2254
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova G; Wiman KG
Book chapter: 25 YEARS OF P53 RESEARCH. 2007;p. 399-419
Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy
Selivanova G; Bykov VJN; Wiman KG
Book chapter: APOPTOSIS AND CANCER THERAPY. 2006;p. 891-912
Cancer Therapy by Reactivation of the p53 Apoptosis Pathway
Stridh H; Bykov VJN; Selivanova G; Wiman KG
Conference publication: ACTA PHARMACOLOGICA SINICA. 2006;27:412-413
Identifying and charactering novel p53 regulated genes for potential anticancer therapy
Liu T; Laurell C; Selivanova G; Lundeberg J; Nilson P; Wiman KG
Letter: NATURE MEDICINE. 2005;11(11):1136-1137
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro -: Reply
Grinkevich V; Issaeva N; Hossain S; Pramanik A; Selivanova G
Published conference paper: BIOELECTROMAGNETICS. 2005;26(3):173-184
915 MHz microwaves and 50 Hz magnetic field affect chromatin conformation and 53BP1 foci in human lymphocytes from hypersensitive and healthy persons
Belyaev IY; Hillert L; Protopopova M; Tamm C; Malmgren LOG; Persson BRR; Selivanova G; Harms-Ringdahl M
Conference publication: ANNALS OF ONCOLOGY. 2005;16:23-24
Mutant p53 reactivation as a novel strategy for cancer therapy
Wiman KG; Stridh H; Zache N; Rökaeus N; Issaeva N; Hammarsund M; Shen JF; Bergman J; Westman J; Selivanova G; Bykov VJN
Conference publication: BLOOD. 2005;106(11):472B
RITA activates p53 function in chronic lymphocytic leukaemia cells and induces apoptosis.
Nahi H; Merup M; Möllgård L; Selivanova G; Paul C
Review: CURRENT CANCER DRUG TARGETS. 2004;4(5):385-402
p53: Fighting cancer
Selivanova G
Book chapter: TRANSCRIPTION FACTORS: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY. 2004;p. 209-258
The p53 Transcription Factor as Therapeutic Target in Cancer
Asker C; Bykov VJN; Mendez-Vidal C; Selivanova G; Wilhelm MT; Wiman KG
Book chapter: TUMOR SUPPRESSING VIRUSES, GENES, AND DRUGS. 2002;p. 397-415
Functional Rescue of Mutant p53 as a Strategy to Combat Cancer
Selivanova G; Wiman KG
Conference publication: CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION. 2002;11(10):1227S-1228S
Distinct p53 domains recognize different type of lesions
Protopopova M; Selivanova G
Review: CURRENT OPINION IN INVESTIGATIONAL DRUGS. 2001;2(8):1136-1141
Mutant p53: the loaded gun.
Selivanova G
Conference publication: CLINICAL CANCER RESEARCH. 2001;7(11):3749S
Restoration of the tumor suppressor function of mutant p53 by a low molecular weight compound.
Bykov VJ; Issaeva N; Shilov A; Bergman J; Selivanova G; Wiman KG
Conference publication: CLINICAL CANCER RESEARCH. 2001;7(11):3792S
Restoration of transcriptional transactivation function of mutant p53 by small molecules.
Issaeva N; Shilov A; Bykov V; Wiman K; Selivanova G
Other: ONCOGENE. 1995;10(9):1869-1874
RESTING B-CELLS, EBV-INFECTED B-BLASTS AND ESTABLISHED LYMPHOBLASTOID CELL-LINES DIFFER IN THEIR RB, P53 AND EBNA-5 EXPRESSION PATTERNS
SZEKELY L; POKROVSKAJA K; JIANG WQ; SELIVANOVA G; LOWBEER M; RINGERTZ N; WIMAN KG; KLEIN G
Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1995;:325
P53 BINDS SINGLE-STRANDED-DNA ENDS THROUGH C-TERMINAL DOMAIN AND INTERNAL DNA SEGMENTS VIA THE MIDDLE DOMAIN
SELIVANOVA G; BAKALKIN G; YAKOVLEVA T; KISELEVA E; SZEKELY L; TERENIUS L; WIMAN KG
Review: ADVANCES IN CANCER RESEARCH. 1995;66:143-180
P53 - A CELL-CYCLE REGULATOR ACTIVATED BY DNA-DAMAGE
SELIVANOVA G; WIMAN KG
Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1995;:77
P53 BINDS SINGLE-STRANDED-DNA ENDS THROUGH C-TERMINAL DOMAIN AND INTERNAL DNA SEGMENTS VIA THE MIDDLE DOMAIN
SELIVANOVA G; BAKALKIN G; YAKOVLEVA T; KISELEVA E; SZEKELY L; TERENIUS L; WIMAN KG
Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1994;:181
P53 BINDS SINGLE-STRANDED-DNA ENDS AND CATALYZES DNA RENATURATION AND STRAND TRANSFER
SELIVANOVA G; BAKALKIN G; YAKOVLEVA T; MAGNUSSON KP; SZEKELY L; KISELEVA E; KLEIN G; TERENIUS L; WIMAN KG
Show more

Grants

Targeting p53 to kill tumor cells, reprogram cancer-associated fibroblasts and boost anti-cancer immune response
Swedish Research Council
1 January 2020 - 31 December 2023
To tame p53 and have a long cancer-free life, continued
Swedish Cancer Society
1 January 2018
To tame p53 to live longer without cancer
Swedish Cancer Society
1 January 2017
Targeting p53 pathway to combat cancer: from lab bench to patient
Swedish Research Council
1 January 2016 - 31 December 2019
To tame p53 to live longer without cancer
Swedish Cancer Society
1 January 2016
To tame p53 to live longer without cancer
Swedish Cancer Society
1 January 2015
To target p53 networks to fight cancer: from the lab bank to the hospital
Swedish Cancer Society
1 January 2014
Novel treatment of advanced melanoma by targeted pro-senescence therapy combined with immunotherapy
Knut and Alice Wallenberg Foundation
1 January 2013 - 1 January 2018
Rational design of synergistic combinations of target-specific anti-cancer drugs
Ragnar Söderberg Foundation
1 January 2012 - 31 December 2014
Targeting p53 pathway: from lab bench to patient
Swedish Research Council
1 January 2011 - 31 December 2015

Employments

Professor, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 2010-

Degrees and Education

Docent, Karolinska Institutet, 2002

About me

Articles

All other publications

Grants

Employments

Degrees and Education

News from KI

Events from KI